cell

Cell Therapeutics, Inc. Management to Discuss Today's Announcement of Interim Pixantrone Study Results

SEATTLE, July 11, 2007 /PRNewswire-FirstCall/ -- On Wednesday,July 11, 2007, at 1:30 p.m. Pacific/4:30 p.m. Eastern/10:30 p.m.Central European Time members of Cell Therapeutics, Inc.'s (CTI)management team will host a conference call to discuss today'sannouncement of the interim results of its phase II/III RAPID trialcomparing CHOP-R to CPOP-R, in which pixantrone is substituted fordoxor...

Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis

LEVERKUSEN, Germany - Biofrontera AG (DSE: B8F) announces todaythat it has received very positive results in the dose finding partof its phase IIb/III clinical trial started in autumn 2006. BF-200ALA, a gel that combines the active substance 5-aminolevulinic acid(ALA) with the nanoemulsion BF-200, was strongly and significantlysuperior to placebo in the treatment of actinic keratosis. BF-...

Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting System's Success in Mouse Model Reported in Cancer Cell

HOUSTON, July 9, 2007 - A molecularly engineeredtherapy selectively embeds a gene in pancreatic cancer that shrinksor eradicates tumors, inhibits metastasis, and prolongs survivalwith virtually no toxicity, researchers from The University ofTexas M. D. Anderson Cancer Center report in the July 9 edition ofCancer Cell. "This vehicle, or vector, is so targeted and robust in itscanc...

ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul 2, 2007 - ViaCell, Inc.(NASDAQ: VIAC) today announced that Marc D. Beer, President andChief Executive Officer of ViaCell, will present an update on itsbusiness activities and product pipeline at the C.E. Unterberg,Towbin Emerging Growth Opportunities Conference on Tuesday, July10, 2007 at 3:00 p.m. at the Mandarin Oriental Hotel in New York,NY. A live...

Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

BLOOMFIELD, N.J., July 05, 2007 /PRNewswire/ -- AlfacellCorporation today announced that Lawrence A. Kenyon, executive vicepresident, chief financial officer and corporate secretary, willpresent an overview of the company's product development programsat 8 a.m. EDT on Thursday, July 12, 2007, at the C.E. Unterberg,Towbin Emerging Growth Opportunities Conference in New York. The aud...

Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease

Adult stem cells cultivated from patients' own blood canpotentially improve the quality of life for patients whose lowerextremities are affected by peripheral vascular disease, accordingto a study in China. SHENZHEN, China, July 02, 2007 /PRNewswire/ -- BeikeBiotechnology Co., Ltd. (<a target="_blank" href="http://www.beikebiotech.com/">http://www.beikebiotech.com )today announced tha...

Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics

PHILADELPHIA, July 3, 2007 ? Researchers in Slovakia havebeen able to derive mesenchymal stem cells from human adipose, orfat, tissue and engineer them into “suicide genes” that seek out and destroy tumors like tiny homing missiles. This gene therapy approach is a novel way to attack smalltumor metastases that evade current detection techniques andtreatments, the researchers...

Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types

Results also show significant additional protection againstinfection with virus types beyond 16 and 18 with the GSK cervicalcancer candidate vaccine PHILADELPHIA, June 27, 2007 /PRNewswire-FirstCall/ -- Resultsfrom an interim analysis of a Phase III study show thatCERVARIX(R), the GlaxoSmithKline cervical cancer candidate vaccine,provides up to 100 percent protection against advanced prec...

Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study

SYDNEY, Australia--(BUSINESS WIRE)--Jun 27, 2007 - PrimeCell(TM)Therapeutics LLC (http://www.primecelltherapeutics.com) todayannounced that it provided research support and pre-clinicalstudies for a clinical trial to assess the safety, feasibility andefficacy of implanting autologous bone marrow stem cells intospinal cord injury (SCI) patients. Dr. Luis Geffner presented a preliminary rep...

Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company

Statement by Sandra C. Raymond, President & CEO of the LupusFoundation of America, Inc. WASHINGTON, June 27, 2007 /PRNewswire-USNewswire/ -- The LupusFoundation of America, Inc. and more than 1.5 million Americanswith lupus have been awaiting the preliminary findings of the PhaseIII clinical trials for CellCept(R), a potential treatment forlupus kidney disease being tested by Aspreva...

Aspreva and Roche Announce Preliminary Results for Phase III Study Evaluating CellCept in Lupus Nephritis

VICTORIA, BC, Canada and BASEL, Switzerland, June 27 /CNW/ -Aspreva Pharmaceuticals Corporation (NASDAQ: ASPV; TSX: ASV) andRoche today released preliminary results for a clinical trialcomparing CellCept (oral mycophenolate mofetil, MMF) to intravenouscyclophosphamide (IVC), which is the current standard of care, forinducing treatment response in the induction phase of patientssuffering fro...

In Vitro and In Vivo Data Show Alfacell's Onocanse is Active Against Naive and Chemoresistant Neuroblastoma Cells

Pre-Clinical Results Demonstrate Potential of ONCONASE forTreatment of Neuroblastoma BLOOMFIELD, N.J., June 27, 2007 /PRNewswire-FirstCall/ --Alfacell Corporation today announced that new data show ONCONASE,the company's lead drug candidate, is active against naive andchemoresistant neuroblastoma cells. The pre-clinical in vitro and in vivo data published in CancerLetters (2007; Vo...

Bio-Matrix Scientific's Dr. O'Neill Sees University of Pittsburgh's Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells

SAN DIEGO--(BUSINESS WIRE)--Jun 27, 2007 - The University ofPittsburgh School of Health Sciences issued the following study andpress release, "Scientists Culture Blood-Forming Stem Cells fromHuman Fat Tissue," June 15, 2007, Science Daily: "Researchers atthe University of Pittsburgh School of Medicine have successfullyisolated and cultured human hematopoietic stem cells from fat, oradipose...

Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer

WAILEA, Hawaii and SUNNYVALE, Calif., June 27, 2007/PRNewswire-FirstCall/ -- Pharmacyclics, Inc. today announcedpreliminary results from two open-label, multi-center Phase 2clinical trials supporting the potential use of Xcytrin(R)(motexafin gadolinium) Injection, the company's lead productcandidate, in combination with Alimta(R) (pemetrexed) and incombination with Taxotere(R) (docetaxel...

Publication Confirms that EpCAM, the Target for Two of Micromet's Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers

BETHESDA, Md., June 26, 2007 /PRNewswire-FirstCall/ -- Micromet,Inc. , a biopharmaceutical company focusing on the development ofnovel, proprietary antibody-based products for cancer, inflammatoryand autoimmune diseases, announced that a study published recentlyin the Proceedings of the National Academy of Sciences (1) supportsthe findings of several other studies that EpCAM (CD326), whic...

An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes

CHICAGO--(BUSINESS WIRE)--Jun 25, 2007 - New data from aninvestigational study released at the American Diabetes Association(ADA) 67th Annual Scientific Sessions showed that initialcombination therapy with Januvia(TM) (sitagliptin) and metformindemonstrated significant improvement in markers of beta cellfunction in patients with type 2 diabetes. Pancreatic islet betacell function determines...

HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove Superior at International Conference

BOSTON--(BUSINESS WIRE)--Jun 25, 2007 - HepaLife Technologies, Inc.(OTCBB: HPLF) (FWB: HL1) (WKN: 500625) today announced that newdata presented at an international influenza research conferencedemonstrates that HepaLife's patented PBS-1 cell line outperformscurrent cell technologies at replicating human influenza virusinside its cells. The most important step towards the production ofa cel...

BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting

Independent Study Indicates 20-50% Improvement in Post-PreservationFunctional Recovery of Peripheral Blood Stem Cells for CancerTherapy BOTHELL, Wash., June 25, 2007 /PRNewswire-FirstCall/ -- BioLifeSolutions Inc. , a leading developer and marketer of proprietaryhypothermic storage and cryopreservation media products for cells,tissues, and organs, today presented data from an independent...

Infertile Voice Supports Stem Cell Research: RESOLVE Calls for Patient Options in Using Frozen Embryos

New survey shows more than half of infertile couples willing todonate unused embryos for stem cell research BETHESDA, Md., June 20, 2007 /PRNewswire/ -- RESOLVE: TheNational Infertility Association issued the following statementtoday, in anticipation of President Bush's veto of federallegislation that would loosen current limitations on stem cellresearch: "President Bush is choosin...

Fact Sheet: Advancing Stem Cell Research While Respecting Moral Boundaries

WASHINGTON--(BUSINESS WIRE)--Jun 20, 2007 - Today, President BushSigned An Executive Order To Strengthen Our Nation's Commitment ToResearch On Pluripotent Stem Cells. Scientists have recently shownthey have the ingenuity and skill to pursue the potential benefitsof pluripotent stem cell research - research on cells that have thepotential to develop into nearly all the cell types and tissues...

President Bush Ignores America's Plea for Support of Stem Cell Research

WASHINGTON, June 20, 2007 /PRNewswire-USNewswire/ -- Thefollowing statement may be attributed to Sean Tipton, president,Coalition for the Advancement of Medical Research (CAMR): "In the face of spiraling health care costs, President Bush onceagain used the stroke of his veto pen deliberately to hamper theprogress of scientific and medical research, as well as endangerthe future hea...

The Christopher and Dana Reeve Foundation Expresses Disappointment Over President Bush's Veto of the Stem Cell Research Enhancement Act

SHORT HILLS, N.J., June 20, 2007 /PRNewswire-USNewswire/ -- TheChristopher and Dana Reeve Foundation (CDRF), the national,non-profit organization dedicated to finding cures and treatmentsfor spinal cord injuries and improving the lives of people livingwith paralysis, today expressed strong disappointment in PresidentBush's veto of the Stem Cell Research Enhancement Act, which wouldhave p...

Obama Statement on Bush Veto of Stem Cell Bill

CHICAGO--(BUSINESS WIRE)--Jun 20, 2007 - Senator Obama todayreleased the following statement in response to President Bush'sveto of Stem Cell Bill: "By vetoing funding for stem cell research once again, thePresident is deferring the hopes of millions of Americans who donot have the time to keep waiting for the cure that may save orextend their lives. The promise that stem cells hold does...

Remarks by President Bush on Stem Cell Veto and Executive Order

WASHINGTON, June 20, 2007 /PRNewswire-USNewswire/ -- Thefollowing is a transcript of remarks by President Bush on stem cellveto and executive order: THE PRESIDENT: Welcome. I'm glad you're here. America is anation that leads the world in science and technology. Ourinnovative spirit is making possible incredible advances inmedicine that could sa...

Apollo's human proteins boost stem cell research

SYDNEY, Australia, June 21, 2007-At a time when Australianscientists are fighting hard to keep pace with overseas researchand development, an Australian biotech company is leading the worldin the production of human proteins for stem cell research. Apollo CEO John Priest said the company's human proteins areunique in the way they help stem cells to develop into specificcell types s...

Pelosi: Bush Veto of Stem Cell Bill Says 'No' to the Hopes of Million of Families Across America

WASHINGTON, June 20, 2007 /PRNewswire-USNewswire/ -- SpeakerNancy Pelosi issued the following statement today in response toPresident Bush's veto of the stem cell bill: "Once again, the President has ignored the will of the Americanpeople, of leading medical researchers, and of a bipartisanmajority of the Congress. His cruel veto says 'no' to the hopes ofmillion of families across...

Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo

ALAMEDA, Calif.--(BUSINESS WIRE)--Jun 21, 2007 - Advanced CellTechnology, Inc. (OTCBB: ACTC) has successfully produced a humanembryonic stem cell (hESC) line without destroying an embryo at itslab in Worcester, Massachusetts. This development was announced byRobert Lanza, M.D., V.P. of Research and Scientific Development ofAdvanced Cell Technology (ACT) on Tuesday at the fifth annualmeeting...

MaxCyte and Medinet to Present at the 13th Annual Meeting of the International Society for Cellular Therapy (ISCT) in Sydney, Australia

"Electroloading of mature dendritic cells with tumor lysatetriggers robust antigen-specific CTL response" GAITHERSBURG, Md., and YOKOHAMA, Japan, June 22, 2007/PRNewswire/ -- MaxCyte, Inc. and Medinet Co., Ltd. announce ajoint poster presentation at the 13th Annual Meeting of theInternational Society for Cellular Therapy. The meeting is beingheld June 24-27, 2007 in Sydney, Australia....

Millipore Corporation Announces New ReNcell Data from Collaboration with ReNeuron

BILLERICA, Massachusetts --- June20, 2007 --- Millipore Corporation today announced the release ofnew data concerning its ReNcell neural stem cell lines. Theresearch was conducted by the Department of Physiology atUniversity College London and ReNeuron Group plc, whose ReNcelldistribution agreement with Millipore was announced in 2006. The data will be presen...

New Flu Vaccine from PepTcell Could Provide Immunity Against All Strains of Influenza Virus

HIGH WYCOMBE, UK 18th June 2007-Previously undisclosedpre-clinical data showing how a new flu vaccine has the potentialto protect against all strains of influenza, including pandemic andannual, was presented today by PepTcell, at the 2007 Options forthe Control of Influenza VI (Options) Conference, in Toronto,Canada. The pre-cli...

Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Geron's Human Embryonic Stem Cell-Based Therapeutic for Heart Failure

MENLO PARK, Calif.--(BUSINESS WIRE)--Jun 19, 2007 - GeronCorporation (Nasdaq: GERN) today reported that research documentingthe scalable production, survival following engraftment andpositive impact on cardiac function in infarcted rats was presentedtoday for GRNCM1, the company's human embryonic stem cell(hESC)-based therapeutic for heart failure, at the InternationalSociety for Stem Cell...

New Flu Vaccine From PepTcell Could Provide Immunity Against All Strains of Influenza Virus

Data Presented at Leading Influenza Conference HIGH WYCOMBE, England, June 18, 2007 /PRNewswire/ -- Previouslyundisclosed pre-clinical data showing how a new flu vaccine has thepotential to protect against all strains of influenza, includingpandemic and annual, was presented today by PepTcell, at the 2007Options for the Control of Influenza VI (Options) Conference, inToronto, Canada....

New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines

Study Results Published in Cancer Research TARRYTOWN, N.Y., June 15, 2007 /PRNewswire-FirstCall/ -- EpiCeptCorporation today announced the results of scientific studies that(1) demonstrate that Azixa(TM) (MPC-6827) is effective in treatingmultiple types of human tumors in animal models, (2) reveal amechanism by which MPC-6827 exerts its effects, and (3) show thatMPC-6827 is not affected b...

Pluristem's PLX Cells Demonstrate Potential to Treat Parkinson's Disease

NEW YORK--(BUSINESS WIRE)--Jun 14, 2007 - Pluristem Life Systems,Inc. (OTCBB:PLRS) (DAX:PJT), a bio-therapeutics Company dedicatedto the commercialization of products for a variety of malignant,degenerative and auto-immune indications, announced today thatPluristem's PLacenta eXpanded (PLX) cells have been demonstrated invitro to have properties that the Company believes gives thesecells th...

Research Indicates Geron's Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System

MENLO PARK, Calif.--(BUSINESS WIRE)--Jun 11, 2007 - GeronCorporation (Nasdaq:GERN) today announced the presentation ofresearch studies indicating that GRNOPC1, the company's humanembryonic stem cell (hESC)-based therapeutic for the treatment ofspinal cord injury, evades a direct attack by the human immunesystem. Presented by Geron scientist Ross Okamura at the Federation ofClinical Immun...

Orchestra Therapeutics Announces New Phase II Clinical Data on NeuroVax Demonstrating Marked Expansion of Regulatory T Cell Populations in Patients With Multiple Sclerosis

- New Data from Open-Label Study Presented at Federation ofClinical Immunology Societies (FOCIS) Annual Meeting - CARLSBAD, Calif., June 11, 2007 /PRNewswire-FirstCall/ --Orchestra Therapeutics, Inc. (Bulletin Board: OCHT) announced todaypositive new data from its completed Phase II open-label study ofNeuroVax(TM), an investigational T Cell Receptor (TCR) peptidevaccine for the treatment...

Favrille Announces Data From Phase 2 Clinical Trial of FavId for Indolent B-Cell Non-Hodgkin's Lymphoma in Europe

Data Reported at the Congress of the European HematologyAssociation SAN DIEGO, June 11, 2007 /PRNewswire-FirstCall/ -- Favrille,Inc. , a biopharmaceutical company developing patient-specific,active immunotherapies for the treatment of cancer, announcedinterim data from a Phase 2 clinical trial of FavId(R) in patientswith indolent B-cell non-Hodgkin's lymphoma (NHL). The data werereported...

ApoCell's Cancer Predictive Index Helps Oncologists Select the Most Effective Targeted Drug Therapy

HOUSTON--(BUSINESS WIRE)--Jun 7, 2007 - ApoCell, Inc. presented theresults of a study conducted by researchers at the University ofChicago and ApoCell at the 2007 annual meeting of the AmericanSociety of Clinical Oncology (ASCO) held in Chicago in early June.The study showed that ApoCell's advanced pharmacodynamic biomarkerassay technology provides reliable predictive data of clinicalrespon...

Refrigerated Stem Cells Survive 12 Times Longer with ProtoKinetix's AAGP

VANCOUVER, British Columbia--(BUSINESS WIRE)--Jun 7, 2007 - As afollow up to ProtoKinetix Inc.'s (OTCBB:PKTX) May 23, 2007 pressrelease related to cryopreserved (or frozen) cells treated withAAGP(TM), in collaboration with the University of Helsinki,Finland, ProtoKinetix has recently finished a set of trialsdesigned to determine whether AAGP(TM) treated cells could surviveafter preservation...

Gloucester Pharmaceuticals Reports Positive Interim Phase II Data on Romidepsin for T-Cell Lymphomas at the 2007 American Society of Clinical Oncology Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 5, 2007 - GloucesterPharmaceuticals, Inc., a privately held cancer therapeuticsdevelopment company, today announced that data for romidepsin as atreatment for cutaneous T-cell lymphoma (CTCL) and peripheralT-cell lymphoma (PTCL) were presented at the American Society ofClinical Oncology (ASCO) Annual Meeting being held in Chicago, IL.The data presented...